



• Dermatology  
beyond the skin

# **LEO Pharma Methodological Note**

**Disclosure under EFPIA and Pharma Industry Finland (PIF)**

**for LEO Pharma Oy, Finland**

**2019**

# Contents

|             |                                                             |           |
|-------------|-------------------------------------------------------------|-----------|
| <b>1</b>    | <b>Introduction</b>                                         | <b>3</b>  |
| <b>2</b>    | <b>Purpose</b>                                              | <b>3</b>  |
| <b>3</b>    | <b>Terminology and Definitions</b>                          | <b>3</b>  |
| <b>4</b>    | <b>Global Healthcare Compliance Process</b>                 | <b>5</b>  |
| 4.1         | Identification of HCP/HCO/Patient Organization              | 6         |
| <b>5</b>    | <b>Scope and Content of HCP/HCO ToV Disclosure</b>          | <b>6</b>  |
| 5.1         | Individual Disclosure                                       | 6         |
| 5.2         | Self-incorporated HCPs                                      | 7         |
| 5.3         | Aggregated Disclosure                                       | 7         |
| 5.4         | Research and Development                                    | 7         |
| 5.5         | Investigator Initiated Studies (IIS)                        | 7         |
| 5.6         | ToVs in case of partial attendance or cancellation          | 7         |
| 5.7         | Master agreements                                           | 8         |
| 5.8         | Indirect ToVs                                               | 8         |
| 5.8.1       | Indirect ToV – through an HCO                               | 8         |
| 5.8.2       | Indirect ToV – through a PCO                                | 8         |
| 5.8.3       | Indirect ToV - Distributors                                 | 9         |
| 5.8.4       | Indirect ToV – Market Research Studies                      | 9         |
| <b>5.9</b>  | <b>Financial data</b>                                       | <b>9</b>  |
| 5.9.1       | Currency                                                    | 9         |
| 5.9.2       | VAT                                                         | 10        |
| <b>5.10</b> | <b>Cross-Border Collaborations</b>                          | <b>10</b> |
| <b>5.11</b> | <b>Consent Management</b>                                   | <b>10</b> |
| 5.11.1      | Consent collection                                          | 10        |
| 5.11.2      | Management of Recipient consent withdrawal                  | 10        |
| 5.11.3      | Management of Recipient's request                           | 10        |
| 5.11.4      | Partial consent                                             | 11        |
| <b>5.12</b> | <b>Disclosure form</b>                                      | <b>11</b> |
| 5.12.1      | Date of publication                                         | 11        |
| 5.12.2      | Disclosure platform                                         | 11        |
| 5.12.3      | Disclosure language                                         | 11        |
| <b>5.13</b> | <b>Disclosure exclusions</b>                                | <b>11</b> |
| 5.13.1      | LEO Pharma employees attendance at conferences              | 11        |
| 5.13.2      | Support for publications                                    | 11        |
| <b>6</b>    | <b>Disclosure of ToVs provided to Patient Organizations</b> | <b>12</b> |
| <b>7</b>    | <b>Retention</b>                                            | <b>13</b> |
| <b>8</b>    | <b>References</b>                                           | <b>13</b> |

## 1 Introduction

Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs) provide the LEO Pharma Group with valuable, independent and expert knowledge from their experience within the field of dermatology and other areas that the LEO Pharma Group operates within. The expertise of HCPs and HCOs helps the LEO Pharma Group improve patients' quality of life.

The LEO Pharma Group believes it is fair and reasonable that HCPs and HCOs are compensated for the legitimate services and expertise that they provide. In addition, the LEO Pharma Group supports the education of HCPs and activities within healthcare or research. At the same time, the LEO Pharma Group acknowledges the need for and is committed to ensuring transparency of such Transfers of Value (ToV) provided to HCPs and HCOs, as required by the EFPIA Code of Practice, as well as PIF Code of Ethics.

The LEO Pharma Group also interacts with Patient Organizations to improve research and support education. In the same manner as for HCPs and HCOs, the LEO Pharma Group is committed to ensuring transparency of its engagements with Patient Organizations in accordance with the EFPIA Code of Practice and PIF Code of Ethics.

To ensure that the LEO Pharma Group's engagements with HCPs, HCOs and Patient Organizations are in compliance, appropriate, properly documented, transparent and do not compromise the independence of the HCP, HCO or Patient Organization, the LEO Pharma Group has developed a healthcare compliance framework. The healthcare compliance framework supports the LEO Pharma Group in avoiding conflicts of interest, and creates transparency when engaging with HCPs, HCOs and Patient Organizations locally, and across borders.

## 2 Purpose

This methodology note describes in detail how the LEO Pharma Group, including LEO Pharma Oy, ensures transparency with regards to the ToVs that the LEO Pharma Group provides to HCPs, HCOs and Patient Organizations. It outlines the general principles underlying the disclosure of ToVs by the LEO Pharma Group and describes the general principles by which the LEO Pharma Group has ensured that the ToV data is complete and accurate.

The methodology note is a requirement outlined in the EFPIA Code of Practice, Chapter 5, and will be available to the public.

## 3 Terminology and Definitions

### Cross-border Collaborations

Any Engagement between LEO Pharma and an HCP/HCO/Patient Organization where the HCP/HCO/Patient Organization is located in a country different from:

- the country of the activity, or
- the country of the LEO Pharma contracting entity

### Direct ToV

Transfers of Value made directly by an entity within the LEO Pharma Group to an HCP/HCO/Patient Organization.

### Donation/Grant

#### I. General definition

Financial or Non-Financial Support provided by the LEO Pharma Group to an eligible Recipient for an altruistic, professional or scientific, or humanitarian purpose, or to support a specific educational or research project. Donations and Grants are provided without receiving or expecting any benefits in return from the Recipient, but Grants may be conditional upon

certain requirements and obligations agreed between the involved parties. Donations/Grants may take many forms, including financial support, chemical compounds or equipment for research or healthcare purposes and/or medical products.

This definition may vary locally; in which case, the local definition prevails.

## **EFPIA**

European Federation of Pharmaceutical Industries and Associations

## **Healthcare Professional (HCP)**

### **I. General definition**

The definition of an HCP varies from country to country and may include any natural person that is a member of the medical, dental, pharmacy or nursing professions or any other person who, in the course of his/her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product.

## **Healthcare Organization (HCO)**

### **I. General definition**

An HCO is any legal person/entity:

- that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as hospital clinic, foundation, university or other teaching institution or learned society (except for Patient Organisations) or
- through which one or more HCPs provide services.

This definition may vary locally; in which case, the local definition should apply.

## **Healthcare Compliance Person**

Locally appointed person responsible for supporting compliance of activities involving HCPs/HCOs/Patient Organizations, both organized locally and as part of a Cross-Border Collaboration, and who is also responsible for the local disclosure of ToVs provided – by any LEO Pharma entity – to HCPs/HCOs/Patient Organizations with Principle Practice Address in the country within the responsibility of the Healthcare Compliance Person.

## **Indirect ToV**

Transfers of Value made to an HCP/HCO/Patient Organization on behalf of an entity within the LEO Pharma Group through an intermediary (Third Party). The LEO Pharma Group must know about and/or be able to identify the HCP/HCO/Patient Organization that will benefit from the ToV in order for the ToV to be considered an Indirect ToV.

## **LEO Pharma Group**

LEO Pharma A/S (HQ) and any affiliate, production site, regional office, representative office, local sales office, company, cooperation, firm, partner-ship, subsidiary, or other entity controlled by or in common control with LEO Pharma A/S.

## **National Engagement**

An HCP/HCO/Patient Organization engagement made between an entity within the LEO Pharma Group and an HCP/HCO/Patient Organization from the same country as the concerned entity.

## **LEO Pharma Organizer**

The appointed person who has the overall responsibility for the interaction with an HCP/HCO/Patient Organization, no matter where the business unit, department or function of such person is located (e.g. HR, R&D, Sales & Marketing, etc.).

## **Patient Organization**

Not-for-profit organization (including the umbrella organization to which they belong), mainly composed of patients, that represents and/or supports the needs and interests of patients. A Patient who is representing a Patient Organization is considered a representative of the concerned Patient Organization and hence fall in the definition of a Patient Organization.

**Paying Country**

The entity within the LEO Pharma Group that issues a payment/reimbursement or makes any other ToV to a specific HCP/HCO/Patient Organization.

**Professional Conference Organizer (PCO)**

A legal entity specialized in the organization and management of congresses, conferences, seminars and similar events.

**Principal Practice Address**

The address where an:

- HCP performs the majority of his/her healthcare related services
- HCO/Patient Organization has its place of incorporation

**Recipient**

The HCP/HCO/Patient Organization receiving a ToV either directly or indirectly from an entity within the LEO Pharma Group.

**Third Party**

Any company or individual who is not a member of LEO Pharma Group or a LEO Pharma employee, and who:

- is hired to provide products or services to the LEO Pharma Group or to act on behalf of the LEO Pharma Group (i.e. vendor or service provider), or
- enters a business partnership or collaboration with the LEO Pharma Group (i.e. business partner).

The definition includes e.g. contract manufacturing organizations, academic and commercial contract research organizations, consultants, distributors, market research companies, and advertising agencies, organizations, associations, institutions and other parties or persons not affiliated with the LEO Pharma Group.

**Transfer of Value (ToV)**

Any direct or indirect Transfer of Value provided to an HCP/HCO/Patient Organization by the LEO Pharma Group, whether monetary, in kind or otherwise, made, whether for promotional purposes or not, in connection with the development and/or sale of products. This includes, but is not limited to, payments of fees for services, registration fees, sponsorships, travel and the provision of hospitality.

**4 Global Healthcare Compliance Process**

The global process for engaging with HCPs, HCOs and Patient Organizations in the LEO Pharma Group as well as the process for disclosure of ToVs (the Global Healthcare Compliance Process) is aligned with the requirements set out by EFPIA. The implementation of the process in each country must follow the national requirements in alignment with PIF Code of Ethics, in which case additional local procedures may be in place, in order to meet local compliance requirements for HCP/HCO/Patient Organization engagements and the disclosure of ToVs provided to HCPs/HCOs/Patient Organizations by the LEO Pharma Group.

As part of the Global Healthcare Compliance Process, a LEO Pharma unique identifier for each HCP/HCO/Patient Organization is assigned to the Recipient of the ToV, and the ToV is processed in accordance with the LEO Pharma HCP/HCO/Patient Organization finance procedures to ensure that all ToVs to Recipients made in the LEO Pharma finance systems can be captured.

The ToVs are extracted from the finance systems or manually captured by the LEO Pharma Organizer. For ToVs made to HCP/HCOs/Patient Organizations through a Third Party, the Third Party is responsible for tracking and providing the LEO Pharma

Organizer with the ToVs including the master data associated to the HCP/HCO/Patient Organization which is needed for the disclosure.

The Healthcare Compliance Person in Paying Country is responsible for tracking all ToVs provided to HCPs/HCOs/Patient Organizations by his/her LEO Pharma entity, whereas the Healthcare Compliance person in the country of HCP/HCO/Patient Organization is responsible for preparing the local disclosure report(s) containing all ToVs provided by the LEO Pharma Group to HCPs/HCOs/Patient Organizations with Principal Practice Address in the country of the Healthcare Compliance Person.

#### **4.1 Identification of HCP/HCO/Patient Organization**

The LEO Pharma unique identifier assigned to each individual HCP/HCO/Patient Organization ensures 1) unique identification of any HCP, HCO or Patient Organization to whom the LEO Pharma Group is providing a transfer a value (the Recipient of the ToV), and 2) that the ToV made to a specific HCP/HCO/Patient Organization will not be reported more than once due to e.g. errors in the contact details of the HCP/HCO/Patient Organization. The LEO Pharma unique identifier contains the details of the HCP/HCO/Patient Organization needed for disclosure, including the Principal Practice Address.

### **5 Scope and Content of HCP/HCO ToV Disclosure**

The LEO Pharma Group is responsible for disclosing both Direct and Indirect ToVs made on behalf of the LEO Pharma Group to HCPs and HCOs in connection with activities relating to LEO Pharma prescription-only medicines in countries with disclosure requirements. This includes, but is not limited to, payments for the performance of services, registration fees, sponsorships, financial support, travel, hospitality, and other expenses related to an activity involving an HCP and/or HCO.

As described earlier in this document, the LEO Pharma Group has assigned a Healthcare Compliance Person for each country who is overall responsible for ensuring the accurate and complete disclosure of the ToVs in accordance with local requirements. The Healthcare Compliance Person in the country where the HCP/HCO has his/her/its Principal Practice Address (country of HCP) must ensure disclosure of all reportable ToVs in the country of the HCP/HCO, including both National Engagements and Cross-Border Collaborations, regardless of whether they consist of Direct or Indirect ToVs and regardless of whether the ToV has been initiated by the LEO Pharma Group or upon request by the HCP/HCO.

#### **5.1 Individual Disclosure**

The reportable ToV is disclosed under the name of the specific HCP/HCO to whom the ToV was made (individual level) based on the LEO Pharma unique identifier in all cases except i) when the activity performed by an HCP/HCO concerns specific Research & Development services as defined in section 5.4 or ii) when the HCP/HCO did not consent to disclosure, see section 5.11.

The disclosure on an individual level includes, but is not limited to, fee-for-service activities, consultancy advice, advisory board activities, general advice, non-blinded market research, conference registration fees, and all disclosable expenses related to such activities. R&D advisory boards, medical consulting and/or data review not related to a specific clinical trial are also disclosed on an individual basis.

The disclosure on an individual level also includes services in connection with non-interventional **retrospective** studies (such as consultancy advice in relation to a database study and medical chart review study, investigator initiated studies that are retrospective in nature (see section 5.5)), and support for medical writing for independent publications, however see section 5.13.2.

## 5.2 Self-incorporated HCPs

For self-incorporated HCPs, in which case a legal entity (HCO) is owned by one HCP, the reportable ToV is disclosed against the HCP being the recipient of the payment.

## 5.3 Aggregated Disclosure

The reportable ToV is disclosed on an aggregated level in cases where i) the ToV is related to Research & Development Activities, see section 5.4 and, ii) the HCP has not provided his/her consent for disclosure, if required, as described in section 5.11.

## 5.4 Research and Development

Research and Development activities are by EFPIA divided into 3 main activity types: non-clinical study, clinical trial and non-interventional study.

**Non-clinical study:** This category includes any ToVs made to an HCP/HCO in connection with an experiment or a set of experiments in which a test item is examined under laboratory conditions, in greenhouses or in the field to obtain data on its properties and/or its safety. This typically relates to research activities where the LEO Pharma Group requires services performed by an HCP/HCO in order to complete the activity.

**Clinical trial:** This category includes any ToVs made to an HCP/HCO in connection with a clinical trial, such as fees paid to an HCP/HCO in his capacity as international/national coordinating investigator and investigator fees and honorarium in connection with memberships in a data review/monitoring committee, advisory board or medical consulting in relation to a specific clinical trial.

**Non-interventional study:** Includes any ToVs made to an HCP/HCO in connection with a non-interventional **prospective** study, such as fees paid to an HCP/HCO in his capacity as international/national coordinating investigator or principal Investigator.

## 5.5 Investigator Initiated Studies (IIS)

Financial support to an Investigator Initiated Study (IIS) that is retrospective in nature is disclosed on an individual level while financial support to an IIS that is prospective in nature is disclosed on an aggregated level under Research and Development.

Any retrospective IIS is disclosed as fee for service, although the activity is not performed on behalf of the LEO Pharma Group and the LEO Pharma Group is not involved in the planning and conduct of the study. The HCP/HCO is conducting such study at his/her/its own initiative and is assuming all responsibility for the conduct of the study.

## 5.6 ToVs in case of partial attendance or cancellation

If an activity is cancelled, no ToV will be made to the HCP/HCO, unless the HCP/HCO has already performed certain preparatory work that the LEO Pharma Group required to be performed in connection with the activity. The HCP/HCO will be paid in accordance with the terms defined in the agreement with the HCP/HCO, e.g. hourly fee based on hours spent on the preparation, and the ToV will be disclosed in accordance with section 5. In case the LEO Pharma Group has paid any expenses prior to an activity and the activity is cancelled, no ToV will be disclosed on the HCP/HCO given that the HCP/HCO did not receive any benefits from the pre-payment made by the LEO Pharma Group. In cases where an HCP whose attendance at a congress is sponsored by

LEO Pharma does not attend the congress, the related ToV(s) is not disclosed on the condition that the non-attendance can be justified and is documented.

## **5.7 Master agreements**

In connection with master agreements, the HCP/HCO will be paid in accordance with the fee and terms for travel and expense reimbursement described in the master agreement or in the separate work order prepared for each separate activity requested to be performed by the HCP/HCO. The LEO Pharma unique identifier is assigned at the beginning of the collaboration and will remain assigned to the HCP/HCO, and any ToV will be disclosed according to section 5 and within the applicable reporting period where the individual payments were made, see section 5.9.3.

## **5.8 Indirect ToVs**

The LEO Pharma Group may engage with Third Parties who are engaging HCPs/HCOs as part of services delivered to the LEO Pharma Group. It is evaluated for each specific engagement whether ToVs made to HCPs/HCOs by a Third Party on behalf of the LEO Pharma Group are considered Indirect ToVs.

An Indirect ToV generally includes situations where the identity of the HCP/HCO is specified in the contract with the Third Party or the identity of the HCP/HCO benefitting from the ToV is otherwise known by the LEO Pharma Group.

Indirect ToVs are for instance ToVs made in connection with clinical trials sponsored by the LEO Pharma Group where the conduct of the clinical trial, including payments to HCPs/HCOs, is handled through a Contract Research Organisation.

The LEO Pharma Group is disclosing any Indirect ToV on the same level as Direct ToVs, i.e. either on an individual or aggregated level as described above in section 5.

### **5.8.1 Indirect ToV – through an HCO**

The LEO Pharma Group may engage with an HCP indirectly through an HCO. In such cases, the LEO Pharma Group may request performance of services from a specific HCP employed by the HCO, or the HCO may itself decide that a specific HCP employed by the HCO performs the services.

If it can be clearly identified by the LEO Pharma Group that a ToV in such cases is being transferred to the HCP personally via the HCO, such indirect ToV is tracked and disclosed under the individual HCP and not under the HCO

If the LEO Pharma Group cannot confirm that any HCP employed by the HCO receives a personal benefit from the ToV paid to the HCO, such payment is not considered an Indirect ToV and such payments are not disclosed as a ToV under an individual HCP but instead under the HCO.

### **5.8.2 Indirect ToV – through a PCO**

The LEO Pharma Group may provide support / sponsorship to PCOs in connection with educational/scientific activities. The financial assistance can be used for preparation and/or conduct of the educational/scientific event, sponsoring of speakers, registration fees, travel, accommodation, meals and drinks. If an HCP/HCO, as e.g. a scientific committee, speaker, chair or attendee, will receive a ToV by means of the support/sponsorship provided by the LEO Pharma Group, and the LEO Pharma Group knows or can identify the HCP/HCO that will benefit from the ToV, such ToV will be considered an Indirect ToV. Such Indirect ToVs to HCPs/HCOs provided through PCOs will be disclosed under the name of the benefiting HCP/HCO with no mentioning of the name of the PCO and in accordance with section 5.



In case the LEO Pharma Group is providing support / sponsorship to a PCO, but the LEO Pharma group is not able to identify the benefiting HCP/HCO, this ToV will not be disclosed as the PCO is not an HCP/HCO (or Patient Organization) and hence not a Recipient under the EFPIA Code of Practice. However, in order to ensure transparency of the sponsorships provided by the LEO Pharma Group to educational/scientific events, the LEO Pharma Group requires the PCO to publish the sponsorship on the website of the specific conference.

In case an educational/scientific event is organized by an HCO, and not a PCO, any ToV will be disclosed in the name of the HCO, or in the name of any indirectly benefitting HCP.

### **5.8.3 Indirect ToV - Distributors**

The LEO Pharma Group may engage with distributors who promote and distribute LEO Pharma products. In some cases distributors have an arms-length responsibility towards the LEO Pharma Group and act on their own behalf and do not represent or act on behalf of the LEO Pharma Group in the distribution or promotion of products. In such cases, any ToVs provided to HCPs/HCOs by the distributor are not considered Indirect ToVs and will not be disclosed by the LEO Pharma Group.

In cases where a distributor is acting under the instructions of the LEO Pharma Group and is providing a ToV to an HCP/HCO on behalf of the LEO Pharma Group, such ToVs are considered Indirect ToVs and will be disclosed by the LEO Pharma Group and in accordance with this section 5.

### **5.8.4 Indirect ToV – Market Research Studies**

The LEO Pharma Group may engage with a Third Party in order to conduct market research studies or similar activities where the LEO Pharma Group does not know the identity of the HCP/HCO engaged on behalf of the LEO Pharma Group by the Third Party, and the HCP/HCO does not know the identity of the LEO Pharma Group (double-blinded market research). In such cases, the LEO Pharma Group is not able to track and disclose any ToV made to the HCP/HCO by the Third Party on behalf of the LEO Pharma Group and therefore such ToV will not be disclosed.

If an HCP requires to know the identity of the company performing the market research, this will be revealed in accordance with the guidelines in the EphMRA Code of Conduct. However, to protect the anonymity of the respondents/HCPs, the name of the respondents/HCPs will still not be revealed to the LEO Pharma Group and the LEO Pharma Group will therefore not disclose any ToV made in connection with the market research.

For market research studies where the identity of the HCP/HCO is known by the LEO Pharma Group, the LEO Pharma Group requires the Third Party to track the ToV made to the HCP/HCO in order for the LEO Pharma Group to disclose such ToVs.

## **5.9 Financial data**

To ensure that the ToV disclosed by the LEO Pharma Group is consistent, certain decisions have been made on which data points to be used in the capture and tracking of the ToVs.

### **5.9.1 Currency**

The currency used in the disclosure report is the local currency in the country where the disclosure is made (the country of the HCP/HCO).

ToVs not paid in the currency used in the country of the HCP/HCO will be converted into the currency used in the country of the HCP/HCO via a conversion to EURO. The conversion calculations are based on a fixed yearly currency rate.

### **5.9.2 VAT**

The published ToV amounts are exclusive of VAT, except in some cases where the VAT amount cannot be accurately excluded, in which case the disclosed amounts are inclusive of VAT. For payments subject to withholding tax, the published ToV amounts are inclusive of the withholding tax amount.

### **5.9.3 Date of ToV**

The date of the ToV is the date the payment/reimbursement was made, i.e., the date the payment was cleared in the finance system (clearing date), and not the date the services were provided by the HCP/HCO. For reimbursements in relation with investigator meetings, the date that the ToV was submitted for payment by the LEO Pharma Organizer is used as date of ToV.

For Indirect ToVs related to events such as congresses, the date of activity will be used as date of ToV, whenever possible, for the following types of expenses: congress registration, travel and accommodation.

### **5.10 Cross-Border Collaborations**

Any ToVs made in connection with a Cross-Border Collaboration are tracked by the Paying Country, as described previously. The ToVs from the Paying Country are made available to the Healthcare Compliance Person in the country of the HCP/HCO for disclosure. This process ensures that the LEO Pharma Group discloses not only ToVs from National Engagements, but also all ToVs from Cross-Border Collaborations. If disclosure is not related to Research and Development, the Healthcare Compliance Person in the country of the HCP must ensure that consent has been collected for the specific HCP, see section 5.11.

### **5.11 Consent Management**

In a number of countries, the LEO Pharma Group is obliged to obtain consent from the individual HCP for the disclosure of the HCP's personal data and the ToVs made to the HCP. If such disclosure and pertaining consent is required as per local law and requirements, the Healthcare Compliance Person in the country of HCP ensures that consent from the HCP is obtained, both in connection with Direct and Indirect ToVs, in accordance with local requirements and local data protection laws. In case consent for disclosure is also required for HCOs in a given country according to local data protection laws, it is the responsibility of the Healthcare Compliance Person in the country of the HCO to obtain such consent.

#### **5.11.1 Consent collection**

The consent, if required according to local requirements and local data protection laws, is obtained in a separate consent agreement that covers consent for disclosure of all ToVs provided to an HCP within the given reporting period.

#### **5.11.2 Management of Recipient consent withdrawal**

The HCP can withdraw his/her consent at any time. In such case, the LEO Pharma Group will disclose the related ToVs on an aggregated level and will re-publish the disclosure report, if the data was already published.

Withdrawal of consent is managed by the Healthcare Compliance Person in the country of the HCP.

#### **5.11.3 Management of Recipient's request**

A request from an HCP for withdrawal of his/her consent can be received by any employee in the LEO Pharma Group, who then needs to inform the Healthcare Compliance Person in the country of the HCP for further handling.

#### 5.11.4 Partial consent

The Healthcare Compliance Person in the country of the HCP will verify that consent has been collected before disclosure of the ToVs. Since consent is collected in a separate consent agreement on an HCP level, covering all ToVs within a given disclosure period, all ToVs made for that specific HCP will either be disclosed on an individual or an aggregated level (except ToVs in connection with Research and Development) within a given disclosure period.

This means that if an individual HCP receives a number of ToVs from the LEO Pharma Group throughout the reporting period and for some reason decides to withdraw his/her consent for one or more of those ToVs, the LEO Pharma Group will disclose all of the ToVs provided to the HCP on an aggregated level.

#### 5.12 Disclosure form

For the disclosure, the country-specific applicable disclosure template(s) will be used. The ToVs will be disclosed in accordance with the country-specific requirements.

##### 5.12.1 Date of publication

13<sup>th</sup> of June 2020

##### 5.12.2 Disclosure platform

LEO Pharma Oy website [www.leo-pharma.fi](http://www.leo-pharma.fi)

##### 5.12.3 Disclosure language

English

#### 5.13 Disclosure exclusions

The LEO Pharma Group has excluded certain ToVs made to HCPs/HCOs from the disclosure in accordance with the excluded disclosures stated in the EFPIA Code of Practice, Section 23.03 and PIF Code of Ethics, such as meals and drinks.

In addition, in some cases the LEO Pharma Group provides certain non-financial support to HCPs/HCOs that cannot be assigned a monetary value, and the LEO Pharma Group has evaluated that these transfers of non-financial support are not to be considered a transfer of value, see section 5.13.2. Such ToV will also be excluded from the ToVs for disclosure.

##### 5.13.1 LEO Pharma employees attendance at conferences

In cases where LEO Pharma employees sign up for a conference for regular conference attendance through the standard registration webpage, the LEO Pharma Group does not consider this ToV disclosable and it would be part of ordinary course purchases.

##### 5.13.2 Support for publications

Literature publications that relate to **LEO Pharma originated data and analyses** may be developed collaboratively between an HCP (external author) and the LEO Pharma Group (internal author). In accordance with Good Publication Practice for Communicating Company-Sponsored Medical Research (GPP3) and as stated in the LEO Pharma Group guideline on Scientific, Medical and/or Technical Publications, the LEO Pharma Group does not pay honoraria to authors. Instead, authors contribute to these publications freely by using their time and intellectual resources.

To facilitate the development of publications so that the LEO Pharma Group can meet the obligation to publish results from clinical trials and other research activities in a timely manner, often professional medical writers are used. They can be employees of the LEO Pharma Group or from an external medical writing agency.

Support where the LEO Pharma Group provides a medical writer to an HCP in order to assist the HCP in a publication related to LEO Pharma originated data and analysis is not considered a ToV to the HCP as 1) no fee-for-service activity occurs whereby the HCP obtains no financial benefit, and 2) the value of the support provided by the LEO Pharma Group to authors is to society at large, the scientific community, patients, and the LEO Pharma Group, as it speeds up the process in which we share data, analysis, and interpretation to increase the overall knowledge about our products/patient solutions in development and in clinical use, i.e. there is no value to be transferred to the HCP.

However, the LEO Pharma Group will disclose editorial service fees provided to a medical writer to support an HCP in a publication that is made independent of the LEO Pharma Group in the name of the HCP Author in the fee-for-service category.

For all publications supported by the LEO Pharma Group, the LEO Pharma Group requires transparency and the (co)authorship and contributorship, including any financial contributions from the LEO Pharma Group will be mentioned.

## **6 Disclosure of ToVs provided to Patient Organizations**

The LEO Pharma Group is committed to ensuring transparency in its relationship with Patient Organizations and will, in accordance with the EFPIA Code of Practice and PIF Code of Ethics, make publicly available any ToVs and non-financial support provided by the LEO Pharma Group to Patient Organizations in countries with disclosure requirements.

In accordance with the Global Healthcare Compliance Process as described in section 4 of this document, the Healthcare Compliance Person in the country of the Patient Organization is responsible for preparing the disclosure report with the Direct and Indirect ToVs provided to Patient Organizations from his/her country and disclosing such ToVs in accordance with local disclosure requirements.

Where applicable according to local disclosure requirements, a global LEO Pharma Patient Organization disclosure template will be used by the LEO Pharma entity containing, as a minimum, the following information:

- Country of Patient Organization
- Name of Patient Organization
- Address of Patient Organization
- Type of engagement (type of support/contracted services)
- Type of ToV (financial/non-financial)
- Description of the engagement (description of the nature of the support/contracted services)
- Amount/non-financial support (where no meaningful monetary value can be assigned)
- Currency
- LEO Pharma Paying Country

The LEO Pharma Patient Organization disclosure report per LEO Pharma entity will be disclosed on the local LEO Pharma company website in the country of the Patient Organization, unless local disclosure requirements state otherwise. In case no local LEO Pharma website is available in the country of the Patient Organization, the LEO Pharma Patient Organization disclosure report for that specific country will be published on the global LEO Pharma company website.

The LEO Pharma Patient Organization disclosure reports cover ToVs made within a full calendar year for a given disclosure period and are disclosed on an annual basis by the date specified in the local disclosure requirements. The disclosed amounts are exclusive of VAT where possible.

In countries where consent from the Patient Organization is required in order to disclose the ToVs provided to the Patient Organization on an individual named basis, such consent must be obtained by the Healthcare Compliance Person in the country of the Patient Organization.

The disclosure of ToVs and non-financial support provided to Patient Organizations by the LEO Pharma Group also includes ToVs made by the LEO Pharma Group to individual patients (e.g. for speaker services) who are acting as representatives of a Patient Organization.

## **7 Retention**

The LEO Pharma Group will maintain the relevant records of the ToV data for 6 years after the end of the relevant reporting period, unless a different period is required under applicable national data privacy or other laws or regulations

.

## **8 References**

EFPIA Code of Practice, 2019.

PIF Code of Ethics, 2019.